[Removal of monomeric 239Pu from bones and liver by liposome-encapsulated pentacin].
Dependence of monomeric 239Pu removal from the liver and skeleton by liposome-encapsulated pentacine on dose and concentration of encapsulated chelate was studied in rats. It has been shown that the liposome-encapsulated pentacine (LP) removed 1.5-2.5 times as much 239Pu as free chelate (FP). Dose-effect dependences were logarithmic. The distinction between LP and FP in 239Pu removal from the liver was maximum when chelate had been used in a dose of 50 mumol/kg, with the dose effect upon injection in a large number of liposomes (200 mumol of lipids/kg) being 1.8 times as high as upon injection in smaller number of liposomes (50 mumol/kg). LP doses varying from 100 to 400 mumol/kg, there were no differences between two types of LP; with a LP dose of 400 mumol/kg its action is a bit stronger than that of the chelate. The distinction between LP and FP in 239Pu removal from the skeleton is the greatest with chelate doses exceeding 100 mumol/kg. The use of liposomes in combination with concentrated chelate solution is more effective. Possible interpretation of the features revealed are discussed.
D000818:Animals; D001842:Bone and Bones / Q000378:metabolism*; D003666:Decontamination / Q000379:methods*; D008081:Liposomes / Q000008:administration & dosage*; D008099:Liver / Q000378:metabolism*; D008297:Male; D004369:Pentetic Acid / Q000627:therapeutic use*; D011005:Plutonium / Q000378:metabolism*; D051381:Rats
D008081:Liposomes; D011005:Plutonium; D004369:Pentetic Acid
Nekotorye zakonomernosti vyvedeniia monomernogo 239Pu iz skeleta i pecheni pentatsinom, inkapsulirovannym v liposomakh.